Avia Pharma is launching Nyvigan in Swedish pharmacies. Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida.
Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the intercrural-region and the perianal region.
75% of women are affected at least once during their lifetime es. 90% of those affected are considered uncomplicated and Candida (fungus) is the cause.
Resistance to Candida treatment is a major and growing problem, a sharp increase has been seen in recent decades.
In vitro and in vivo studies show that nystatin has a good effect and there has been no development of resistance in Candida strains. “In addition Nyvigan offers no systemic exposure, no known drug interactions and can be used during any stage of pregnancy and breast-feeding”, says Marie Wikman, Business Unit Director Avia Pharma. For further information, please contact Marie Wikman, marie.wikman@aviapharma.se, +46 708 16 88 16.
